1,072 results match your criteria Lymphoma Malignant Anaplastic Ki 1+


Anaplastic variant of diffuse large B-cell lymphoma: Reappraisal as a nodal disease with sinusoidal involvement.

Pathol Int 2019 Dec;69(12):697-705

Department of Clinical Laboratory, Nagano Prefectural Suzaka Hospital, Nagano, Japan.

Anaplastic variant (av) of diffuse large B-cell lymphoma (DLBCL) is morphologically defined in the 2017 World Health Organization classification, but still an enigmatic disease in its clinicopathologic distinctiveness, posing the differential diagnostic problem from gray zone lymphoma (GZL) and classic Hodgkin lymphoma (cHL). Thirty-one cases previously diagnosed as avDLBCL were reassessed. Of these, 27 (87%) and 4 (13%) were node-based and extranodal diseases, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pin.12871DOI Listing
December 2019

High intratumoural galectin-1 expression predicts adverse outcome in ALK ALCL and CD30 PTCL-NOS.

Hematol Oncol 2020 Feb 1;38(1):59-66. Epub 2020 Jan 1.

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.

Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal-1 expression has not been systematically assessed in peripheral T-cell lymphomas (PTCL). Specimens from 169 nodal PTCL were assessed for intratumoural Gal-1 expression by immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2702DOI Listing
February 2020

Pediatric mediastinal ALK- negative anaplastic large cell lymphoma (Hodgkin-like pattern) in a 13-year-old girl: a case report and review of literature.

Oxf Med Case Reports 2019 Aug 28;2019(8):omz077. Epub 2019 Aug 28.

Department of Pathology, Faculty of Medicine, Tishreen University, Lattakia, Syria.

Anaplastic large-cell Lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that is characterized by an entity of large neoplastic cells labeled by the Ki-1 antibody. It constitutes ~2% of all lymphoid neoplasms and is divided into two main categories: anaplastic large-cell kinase (ALK)+ALCL and ALK-ALCL that is recognized by the absence of ALK expression and mostly affects men at older ages. Thus, in this report we present a rare case of ALK-negative ALCL (ALK-ALCL) that was described and diagnosed in a 13-year-old girl in the mediastinum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/omcr/omz077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735755PMC

Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.

Diagn Pathol 2019 Oct 22;14(1):115. Epub 2019 Oct 22.

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Background: Primary cutaneous CD30+ lymphoproliferative disorders (pc-CD30-LPD) are a group of clonal T cell lymphoproliferative disorders that despite very similar tumor histology follow different and characteristic clinical courses, suggesting a homeostatic role of the tumor microenvironment. Little is known about tumor microenvironment and there is almost no literature about PD-L1 expression in pc-CD30-LPD.

Methods: This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions. Read More

View Article

Download full-text PDF

Source
https://diagnosticpathology.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13000-019-0900-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805531PMC
October 2019
5 Reads

Lymphomatoid Papulosis and Other Lymphoma-Like Diseases.

Dermatol Clin 2019 Oct 6;37(4):471-482. Epub 2019 Aug 6.

Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA. Electronic address:

Pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica are the 2 main subtypes of pityriasis lichenoides. They represent the acute and chronic forms of the disease; both may have clonal T cells. Several treatment modalities are used, but it has been difficult to determine efficacy because of the possibility of spontaneous remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2019.05.005DOI Listing
October 2019
4 Reads

Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics.

Medicine (Baltimore) 2019 Aug;98(32):e16702

Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

CD30 is a member of the tumor necrosis factor family of cell surface receptors normally expressed in lymphocytes, as well as some lymphomas, but has been described in other malignancies. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that belongs to the insulin receptor superfamily, and is normally expressed in neural cells, but has been detected in several malignancies. There is conflicting data in the literature that describes the expression of these receptors in breast cancer, and the aim of this study is to test the expression of CD30 and ALK in a cohort of Middle Eastern patients with breast carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000016702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709128PMC
August 2019
2 Reads

Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.

J Cutan Pathol 2019 Nov 2;46(11):823-829. Epub 2019 Aug 2.

Dermatopathology Unit, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

Aims: Brentuximab vedotin is a monoclonal anti-CD30 antibody-drug conjugate that has been used to treat a variety of CD30+ neoplasms. The phenomenon of antigen loss has been observed in patients treated with the anti-CD20 antibody rituximab. This study seeks to assess for antigen loss in the setting of recurrent CD30+ neoplasms treated with brentuximab vedotin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13545DOI Listing
November 2019
9 Reads
1.560 Impact Factor

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management.

Histopathology 2019 Dec 6;75(6):787-796. Epub 2019 Oct 6.

School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Aims: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon complication associated largely with textured implants. It is important that the symptoms associated with BIA-ALCL are recognised and that robust pathways are in place to establish the diagnosis. The aim of this paper is to review what is known of the incidence of the disease, current thoughts on pathogenesis, patterns of presentation and pathological features to provide standard guidelines for its diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13932DOI Listing
December 2019
15 Reads

How I treat primary cutaneous CD30 lymphoproliferative disorders.

Blood 2019 08 4;134(6):515-524. Epub 2019 Jun 4.

Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.

The primary cutaneous CD30 lymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and localize to the skin. Current classification systems recognize lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases. In the majority of patients, the prognosis of primary cutaneous CD30 lymphoproliferative disorders is excellent; however, relapses are common, and complete cures are rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019000785DOI Listing
August 2019
8 Reads

Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.

MAbs 2019 Aug/Sep;11(6):1149-1161. Epub 2019 Jun 4.

c Department of Technical Quality, Shanghai Jiaolian Drug Research and Development Co., Ltd , Shanghai , China.

An anti-CD30 antibody-drug conjugate incorporating the antimitotic agent DM1 and a stable SMCC linker, anti-CD30-MCC-DM1, was generated as a new antitumor drug candidate for CD30-positive hematological malignancies. Here, the and pharmacologic activities of anti-CD30-MCC-DM1 (also known as F0002-ADC) were evaluated and compared with ADCETRIS (brentuximab vedotin). Pharmacokinetics (PK) and the safety profiles in cynomolgus monkeys were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2019.1618674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748589PMC
January 2020
27 Reads

RF - Brentuximab as Treatment for CD30 Primary Cutaneous Lymphoma.

Actas Dermosifiliogr 2019 Nov 28;110(9):769-770. Epub 2019 May 28.

Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2018.03.025DOI Listing
November 2019
8 Reads

Linfoma anaplásico de células T grandes primario cutáneo CD30+. Serie de nueve casos.

Gac Med Mex 2019 ;155(2):130-135

Secretaría de Salud, Hospital General "Dr. Manuel Gea González", Departamento de Dermatología.

Introduction: CD30+ anaplastic large T cell lymphoma is a cutaneous primary lymphoma in which there is no evidence of systemic disease; histopathological study is required for its diagnosis.

Objective: To present the cases diagnosed with primary cutaneous CD30+ anaplastic large T-cell lymphoma over a 24-year period in Hospital General "Dr. Manuel Gea González" Department of Dermatology. Read More

View Article

Download full-text PDF

Source
http://gacetamedicademexico.com/frame_esp.php?id=265
Publisher Site
http://dx.doi.org/10.24875/GMM.18004656DOI Listing
November 2019
10 Reads

CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells.

Int J Pharm 2019 Jun 16;564:340-349. Epub 2019 Apr 16.

School of Biological Science and Engineering, South China University of Technology, Guangzhou 510640, PR China; Wenzhou Institute of Biomaterials and Engineering, CNITECH, Chinese Academy of Sciences, Wenzhou, Zhejiang Province 325001, PR China. Electronic address:

Nanoparticles (NPs) conjugated with aptamers have been extensively in recent years, which can efficiently target cancer cells that improve the therapeutic effect. Aptamers (Apt) are small oligonucleotide molecule ligands have specific high-affinity. In this work, we developed a PEG-PLGA nanoparticles (NPs) encapsulated with doxorubicin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2019.04.013DOI Listing
June 2019
2 Reads

Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?

Am J Dermatopathol 2019 Nov;41(11):846-850

Departments of Dermatology.

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, primary cutaneous CD30 lymphoproliferative disorders (pc CD30 LPD) being the second most prevalent. There is evidence that MF and pc CD30 LPD may coexist and share T-cell clonality, suggesting a common origin. These findings were supported by a T-cell receptor clonality assessment by the polymerase chain reaction coupled with capillary electrophoresis, although results produced by this method may be ambiguous. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000372-900000000-9816
Publisher Site
http://dx.doi.org/10.1097/DAD.0000000000001423DOI Listing
November 2019
24 Reads

A first time report on the coocurrence of sarcoidosis and ALK(-) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment.

J Oncol Pharm Pract 2019 Oct 25;25(7):1801-1805. Epub 2019 Mar 25.

2 Department of Pathology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Sarcoidosis is known to be associated with higher incidence of solid tumors and hematological malignancies. ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis. As this rare and highly mortal disease did not respond to classical chemotherapies and showed remission with brentuxumab vedontin treatment, we are presenting our first case reported from Turkey hoping to contribute to the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219837331DOI Listing
October 2019
3 Reads

Challenges of driving CD30-directed CAR-T cells to the clinic.

BMC Cancer 2019 Mar 6;19(1):203. Epub 2019 Mar 6.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA.

Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19. CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-019-5415-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404322PMC
March 2019
33 Reads

Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction.

Mol Cancer Ther 2019 04 1;18(4):780-787. Epub 2019 Mar 1.

Research, Seattle Genetics, Inc., Bothell, Washington.

To provide a better understanding of the pharmacokinetics-pharmacodynamics relationships of antibody-based drugs, we analyzed several chimeric and humanized monoclonal antibodies or antibody-drug conjugates (ADC) for PK and efficacy among four strains of mice. Notably, antibodies and ADCs displayed a dose-dependent drug disposition profile in the plasma of NSG mice. The increased clearance rate in NSG mice resulted in the reduction of antitumor activity of ADCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-0977DOI Listing
April 2019
1 Read

Achieving Reliable Diagnosis in Late Breast Implant Seromas: From Reactive to Anaplastic Large Cell Lymphoma.

Plast Reconstr Surg 2019 03;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):15S-22S

Roma, Italy From the Department of Clinical and Molecular Medicine, Sapienza University, Pathology Unit, Sant'Andrea Hospital.

Late onset of fluid collection surrounding breast implants may represent a serious issue when considering the possibility of breast implant-associated anaplastic large cell lymphoma, a newly recognized type of T-cell malignancy. However, many other factors, including trauma and infections, may be implicated in the formation of non-neoplastic periprosthetic delayed effusions. An appropriate management of late seromas, consisting of ultrasound-guided fluid drainage, cultures, cytology, and immunocytochemical and T-cell clonality studies, should be performed to achieve a correct and prompt diagnosis of breast implant-associated anaplastic large cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRS.0000000000005565DOI Listing
March 2019
9 Reads

Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.

Cancer Lett 2019 04 8;448:84-93. Epub 2019 Feb 8.

NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Combining antibody-drug conjugates (ADCs) with targeted small-molecule inhibitors can enhance antitumor effects beyond those attainable with monotherapy. In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30/ALK anaplastic large cell lymphoma (ALCL). In vitro, anti-CD30-LDM showed strong synergistic antiproliferative activity when combined with crizotinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.02.002DOI Listing
April 2019
12 Reads

The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.

Chin Clin Oncol 2019 Feb 9;8(1). Epub 2019 Jan 9.

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Primary cutaneous CD30+ T cell lymphoproliferative disorders (pcCD30+ T cell LPDs) are a spectrum of pre-malignant to frankly neoplastic lymphoproliferations that comprise lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Although the atypical T cells that are the hallmark of these disorders share the expression of CD30, as the identifying marker, the clinical presentation, histological features and clinical course are vastly different. Furthermore, histopathologic features of pcCD30+ T cell LPDs may overlap with other cutaneous and systemic lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.12.03DOI Listing
February 2019
15 Reads

Primary cutaneous CD8+ and CD30+ T-cell lymphoproliferative disorders: case reports and clinical implications.

Eur J Dermatol 2019 Feb;29(1):39-44

Department of Pathology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels.

Background: CD8+ CD30+ primary cutaneous T-cell lymphomas (PCTCL) are rare entities with overlapping pathological features and variable outcome.

Objectives: We sought to highlight the importance of correlation between pathological findings and clinical presentation for correct classification of the disease.

Materials & Methods: Two cases of CD8+ CD30+ PCTCL were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3493DOI Listing
February 2019
22 Reads

Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.

Dermatol Ther 2019 03 17;32(2):e12835. Epub 2019 Feb 17.

Moffitt Cancer Center, Tampa, Florida.

Brentuximab vedotin is a CD30-antibody/drug conjugate which has demonstrated excellent response in treating CD30-positive mycosis fungoides (MF) and anaplastic large cell lymphoma (ALCL). In this report, we present a patient with CD30-negative MF refractory to multiple other lines of therapy who demonstrated a dramatic response to brentuximab. This paradoxical response may be due to inadequate detection of CD30 expression by immunohistochemical techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12835DOI Listing
March 2019
6 Reads
1.478 Impact Factor

Acitretin combined with NB-UVB in the treatment of cutaneous CD30-positive anaplastic large cell lymphoma.

Dermatol Ther 2019 03 27;32(2):e12834. Epub 2019 Feb 27.

Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.

Cutaneous CD30 lymphoproliferative disorders represent a spectrum of skin lymphatic reticular proliferative diseases, including lymphomatoid papulosis (LYP), primary cutaneous anaplastic large cell lymphoma (PC-ALCL), and borderline lesions between them. Although they all express CD30 as a phenotypic marker and share overlapping immunophenotypic features, they differ in clinical manifestations, pathological features, treatment, and prognosis. LYP is a kind of benign disease characterized by recurrent papules and nodules, and may spontaneously regress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12834DOI Listing
March 2019
13 Reads

CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.

Haematologica 2019 02 10;104(2):226-235. Epub 2019 Jan 10.

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid.

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.197152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355473PMC
February 2019
16 Reads

CD30-Positive Lymphoproliferative Disorders.

Cancer Treat Res 2019;176:249-268

Division of Dermatology, City of Hope National Medical Center, Duarte, CA, USA.

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_12DOI Listing
July 2019
29 Reads

CD30+ T-cell lymphoproliferative disorders.

Chin Clin Oncol 2019 Feb 11;8(1). Epub 2018 Oct 11.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

The term "CD30+ T-cell lymphoproliferative disorders" describes a group of diverse diseases of the skin, subcutaneous tissues and mucosa that range from lesions requiring clinical observation to those necessitating systemic cytotoxic chemotherapy. Careful consideration of both clinical and histopathologic presentation is needed for appropriate diagnosis and treatment. This review will present the current classification of these disorders and potential treatment paradigms. Read More

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/21776
Publisher Site
http://dx.doi.org/10.21037/cco.2018.09.06DOI Listing
February 2019
46 Reads

Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.

Am J Clin Dermatol 2019 Feb;20(1):115-122

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1452, Houston, TX, 77030-4009, USA.

Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin's lymphomas that present in the skin. In early-stage disease, the course is generally chronic and indolent; however, in advanced stages of disease, therapies rarely provide long-lasting responses, and the only potential curative therapy is allogeneic hematopoietic stem-cell transplantation. This has led to the search for novel targeted therapies to better treat more advanced stages of CTCLs that cannot be controlled by typical treatment regimens. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0402-5
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0402-5DOI Listing
February 2019
39 Reads

Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.

Ann Diagn Pathol 2018 Dec 12;37:57-61. Epub 2018 Sep 12.

Weill Cornell Medicine, 1300 York Ave, New York, NY 10065, USA. Electronic address:

Epstein-Barr virus (EBV) has a well-known association with lymphoproliferative disorders of B and T cell origin. EBV-related B cell lymphoproliferative disorders include Hodgkin and Burkitt lymphomas, lymphomatoid granulomatosis, EBV positive diffuse large cell B cell lymphoma of the elderly, as well as B cell lymphomas associated with solid organ transplantation and methotrexate use. EBV-related T cell disorders are primarily represented by NK/T- cell lymphoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10929134183023
Publisher Site
http://dx.doi.org/10.1016/j.anndiagpath.2018.08.004DOI Listing
December 2018
21 Reads

Anaplastic large cell lymphoma of the palate: A case report.

J Stomatol Oral Maxillofac Surg 2019 Apr 3;120(2):172-175. Epub 2018 Oct 3.

Department of Oral Biology, Faculty of Dentistry, Mahidol University, Bangkok, Thailand.

Anaplastic large cell lymphoma (ALCL) is a very rare subtype of T-cell non-Hodgkin's lymphoma (NHL). Similar to other types of NHL, ALCL primarily involves the nodal areas and sometimes it can involve several extranodal sites such as skin, lung and soft tissue. Primary oral involvement of systemic ALCL is very rare. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24687855183018
Publisher Site
http://dx.doi.org/10.1016/j.jormas.2018.09.003DOI Listing
April 2019
35 Reads

Fast-growing Painful Leg Ulcers in a 26-year-old Woman with Systemic Lupus Erythematosus: A Quiz.

Acta Derm Venereol 2019 Feb;99(2):250-252

Department of Dermatology, Venerology and Allergology, University Medical Center, Ruprecht-Karls-University, Im Neuenheimer Feld 440, DE-69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3044DOI Listing
February 2019
7 Reads

Colonic CD30 positive plasmablastic plasmacytoma masquerading as anaplastic large cell lymphoma.

Pathology 2018 10 8;50(6):668-670. Epub 2018 Aug 8.

Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan; Department of Pathology, School of Medicine, Taipei Medical University and National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2018.03.011DOI Listing
October 2018
8 Reads

Primary cutaneous CD30 anaplastic large-cell lymphoma associated with fingolimod.

Br J Dermatol 2018 12 10;179(6):1400-1401. Epub 2018 Oct 10.

Department of Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' Hospitals, NHS Trust, London, U.K.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17003DOI Listing
December 2018
30 Reads

CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL).

Acta Med Indones 2018 Apr;50(2):104-109

Division of Hematology and Medical Oncology, Dharmais Hospital National Cancer Center, Jakarta, Indonesia.

Background: the expression of CD30, CD15, CD50, and PAX5 are used to help in confirming diagnosis of HL and sALCL; however data on the proportion of these markers have not been available. The study was aimed to identify the proportion of CD30, CD15, CD50 and PAX5 expressions and characteristics of patients with HL and sALCL at Dharmais National Cancer Center Hospital between 2005 and 2015.

Methods: a retrospective observational study was conducted using data from medical records and histopathological results of HL and sALCL adult patients who sought treatment at the hospital between 2005 and 2015. Read More

View Article

Download full-text PDF

Source
April 2018
10 Reads

The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.

Authors:
Ikhwan Rinaldi

Acta Med Indones 2018 Apr;50(2):93-95

Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Hodgkin lymphoma is a cancer that can be cured using standard chemotherapy with or without radiation. Although it accounts for only 0.6% of all malignancy worldwide, but it usually affects young adults with median age of 38 years. Read More

View Article

Download full-text PDF

Source
April 2018
9 Reads

[Primary cutaneous lymphoma-a case series of 163 patients].

Hautarzt 2018 Dec;69(12):1014-1020

Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Freiburg, Deutschland.

Background: In addition to a broad and clinically diverse spectrum of known primary cutaneous lymphomas, for which an incidence of 1-3:100,000 is postulated, each year further entities are specified and defined. The goal is the presentation of a case series from daily clinical routine.

Methods: Over a period of 6 years and 2 months, patients consulting the Department of Dermatology, Medical Center University of Freiburg, were registered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-018-4212-8DOI Listing
December 2018
38 Reads

EURAPS Editorial: BIA-ALCL, a brief overview.

J Plast Reconstr Aesthet Surg 2018 06;71(6):785-787

Plastic Surgery Unit, Sant'Andrea Hospital, Via di Grottarossa 1035-39, 00189 Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjps.2018.04.012DOI Listing
June 2018
7 Reads

[Primary cutaneous CD30+ T-cell lymphoproliferation during treatment with fingolimod: Case report and literature review].

Ann Dermatol Venereol 2018 Jun - Jul;145(6-7):433-438. Epub 2018 Apr 17.

Service de dermatologie et d'allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Faculté de médecine, Sorbonne université, 75013 Paris, France. Electronic address:

Background: Fingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2018.02.010DOI Listing
January 2019
17 Reads

CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.

J Clin Pathol 2018 Sep 17;71(9):795-801. Epub 2018 Apr 17.

Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Aim: CD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in DLBCLs and try to find the correlated influences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2018-205039DOI Listing
September 2018
14 Reads
2.920 Impact Factor

SATB1 Defines a Subtype of Cutaneous CD30 Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile.

J Invest Dermatol 2018 08 3;138(8):1795-1804. Epub 2018 Mar 3.

Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. Electronic address:

Cutaneous CD30 lymphoproliferative disorders (LPDs), including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma, comprise the second most common group of cutaneous T-cell lymphomas. Previously, we reported that special SATB1, a thymocyte-specific chromatin organizer, was overexpressed and promoted malignant T-cell proliferation in a portion of CD30 LPDs. Here, we investigated the expression pattern of SATB1 in CD30 LPDs with a large cohort of patient samples, and examined the potential of SATB1 as a molecular marker to classify CD30 LPDs with differential clinicopathological behaviors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X183020
Publisher Site
http://dx.doi.org/10.1016/j.jid.2018.02.028DOI Listing
August 2018
30 Reads

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

Blood 2018 05 5;131(19):2120-2124. Epub 2018 Mar 5.

University of Washington Medical Center, Seattle, WA.

This phase 1 study evaluated frontline brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy) in 26 patients with CD30 peripheral T-cell lymphoma, including 19 with systemic anaplastic large cell lymphoma. All patients (100%) achieved an objective response, with a complete remission (CR) rate of 92%; none received a consolidative stem cell transplant. After a median observation period of 59. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-12-821009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946765PMC
May 2018
35 Reads

CD30-positive primary cutaneous anaplastic large cell lymphoma with coexistent pseudocarcinomatous hyperplasia.

Clin Exp Dermatol 2018 Jul 23;43(5):585-588. Epub 2018 Feb 23.

Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Hospital Oberhausen, University Witten-Herdecke, Oberhausen, Germany.

CD30-positive primary cutaneous anaplastic large cell lymphoma (C-ALCL) is an indolent type of cutaneous lymphoma with favourable clinical prognosis. Pseudocarcinomatous hyperplasia (PCH) is a rare benign epithelial condition that can resemble invasive squamous cell carcinoma both clinically and histopathologically. PCH predominantly occurs in CD30-positive lymphoproliferative disorders. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ced.13416
Publisher Site
http://dx.doi.org/10.1111/ced.13416DOI Listing
July 2018
14 Reads

Diagnosis of anaplastic large-cell lymphoma in a dog using CD30 immunohistochemistry.

J Vet Diagn Invest 2018 May 19;30(3):455-458. Epub 2018 Feb 19.

Departments of Pathobiology and Population Sciences (Pittaway, Szladovits, Suárez-Bonnet, Priestnall), The Royal Veterinary College, University of London, North Mymms, United Kingdom.

Anaplastic large-cell lymphoma or null-cell lymphoma is a clinical entity reported in people, classified according to the unique appearance of large pleomorphic cells that express CD30. Null-cell lymphoma has also been described in dogs when neither CD3 nor CD79α is expressed by the tumor. We describe a case of lymphoma in the dog in which neoplastic cells did not express routine B- or T-lymphocyte markers on flow cytometry or immunohistochemistry; however, cells immunohistochemically labeled for CD30. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1040638718760965DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505805PMC
May 2018
21 Reads

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.

BMC Cancer 2018 02 1;18(1):122. Epub 2018 Feb 1.

Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Background: Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or refractory HL or ALCL suggests efficacy of brentuximab vedotin (SGN-35). Pediatric patients should be given medicines that have been appropriately evaluated for their use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4042-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796474PMC
February 2018
16 Reads

A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30 lymphomas.

Mol Oncol 2018 03 26;12(3):339-355. Epub 2018 Jan 26.

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

CD30 is a 120-kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL). CD30-targeted treatment with antibody-drug conjugates (ADCs) can lead to promising clinical benefit. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/1878-0261.12166
Publisher Site
http://dx.doi.org/10.1002/1878-0261.12166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830626PMC
March 2018
14 Reads

Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

J Clin Exp Hematop 2017 ;57(3):120-142

Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research.

Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a large-cell neoplasm with anaplastic morphology immunostained by the Ki-1 antibody, which recognizes CD30. In 1994, the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion receptor tyrosine kinase was identified in a subset of patients, leading to subdivision of this disease into ALK-positive and -negative ALCL in the present World Health Organization classification. Due to variations in morphology and immunophenotype, which may sometimes be atypical for lymphoma, many differential diagnoses should be considered, including solid cancers, lymphomas, and reactive processes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3960/jslrt.17023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144189PMC
July 2018
15 Reads

[Clinicopathologic characteristics and prognosis of neoplastic cell-rich mixed cellularity classic Hodgkin lymphoma].

Zhonghua Bing Li Xue Za Zhi 2017 Oct;46(10):708-713

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

To investigate the clinicopathologic characteristics of neoplastic cell-rich mixed cellularity classical Hodgkin lymphoma(MCCHL-R) and to compare the prognosis with typical mixed cellularity classic Hodgkin lymphoma(MCCHL). Fifty-four patients with MCCHL-R(the tumor cells >10%) and 65 patients with typical MCCHL identified from 1 721 Hodgkin lymphomas were reviewed to compare the clinicopathological characteristics including morphologic and immunophenotypic features, EBV infection status, clinical therapy and overall survival. The median age of the patients of MCCHL-R was 28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2017.10.010DOI Listing
October 2017
9 Reads

Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a Transgender Woman.

Aesthet Surg J 2017 Sep;37(8):NP83-NP87

Department of Plastic, Reconstructive, and Hand Surgery, Maastricht University Medical Center, Maastricht, the Netherlands. Department of Plastic, Reconstructive, and Hand Surgery, VU University Medical Center, Amsterdam, the Netherlands. Department of Oncology, Netherlands Cancer Institute, Amsterdam. Dutch Nationwide Network and Registry of Histo- and Cytopathology, Houten, the Netherlands. Division of Epidemiology, Netherlands Cancer Institute, Amsterdam. Department of Plastic, Reconstructive, and Hand Surgery, MST, Enschede, the Netherlands, Dutch Society of Plastic Surgery. Division of Plastic, Reconstructive, and Hand Surgery, Maastricht University Medical Center. Department of Pathology, VU University Medical Center. Department of Plastic, Reconstructive, and Hand Surgery, VU University Medical Center. Center of Expertise on Gender Dysphoria at the VU University Medical Center. Division of Pathology, VU University Medical Center. Dutch BIA-ALCL Consortium.

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare but serious complication in patients with breast implants, Patients are at risk of BIA-ALCL whether they receive breast implants for cosmetic reasons or for reconstructive purposes after surgery for breast cancer or prophylactic mastectomy. During the past decade, an increased number of reports have addressed BIA-ALCL. Herein, we describe BIA-ALCL in a transgender woman. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjx098DOI Listing
September 2017
58 Reads

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Blood Cancer J 2017 09 8;7(9):e603. Epub 2017 Sep 8.

Department of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.

CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/bcj.2017.85
Publisher Site
http://dx.doi.org/10.1038/bcj.2017.85DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709754PMC
September 2017
42 Reads